Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR.

Hum Gene Ther. 1999 Nov 1;10(16):2615-26.

PMID:
10566889
2.

Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates.

Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, Wadsworth S, O'Riordan C.

Mol Ther. 2003 Jul;8(1):99-107.

PMID:
12842433
3.

Peptide targeting of adenoviral vectors to augment tumor gene transfer.

Ballard EN, Trinh VT, Hogg RT, Gerard RD.

Cancer Gene Ther. 2012 Jul;19(7):476-88. doi: 10.1038/cgt.2012.23.

4.

Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.

White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S.

Hum Gene Ther. 2008 Dec;19(12):1407-14. doi: 10.1089/hgt.2008.117.

PMID:
18778196
5.
6.

Targeting of high-capacity adenoviral vectors.

Biermann V, Volpers C, Hussmann S, Stock A, Kewes H, Schiedner G, Herrmann A, Kochanek S.

Hum Gene Ther. 2001 Sep 20;12(14):1757-69.

PMID:
11560769
7.

Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time.

Zabner J, Zeiher BG, Friedman E, Welsh MJ.

J Virol. 1996 Oct;70(10):6994-7003.

8.

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.

Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ, Molema G.

Hum Gene Ther. 2004 May;15(5):433-43.

PMID:
15144574
9.

Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity.

Hong SS, Galaup A, Peytavi R, Chazal N, Boulanger P.

Hum Gene Ther. 1999 Nov 1;10(16):2577-86.

PMID:
10566886
10.

Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR.

J Virol. 2002 Mar;76(6):2753-62.

11.

Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.

Espenlaub S, Wortmann A, Engler T, Corjon S, Kochanek S, Kreppel F.

J Gene Med. 2008 Dec;10(12):1303-14. doi: 10.1002/jgm.1262.

PMID:
18837065
12.
14.

Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection.

Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ.

J Clin Invest. 1997 Sep 1;100(5):1144-9.

15.

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

Wortmann A, Vöhringer S, Engler T, Corjon S, Schirmbeck R, Reimann J, Kochanek S, Kreppel F.

Mol Ther. 2008 Jan;16(1):154-62.

PMID:
17848961
16.

Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to lumenal infection.

Stonebraker JR, Wagner D, Lefensty RW, Burns K, Gendler SJ, Bergelson JM, Boucher RC, O'Neal WK, Pickles RJ.

J Virol. 2004 Dec;78(24):13755-68.

17.

Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization.

Kim J, Smith T, Idamakanti N, Mulgrew K, Kaloss M, Kylefjord H, Ryan PC, Kaleko M, Stevenson SC.

J Virol. 2002 Feb;76(4):1892-903.

18.

PEGylated adenovirus for targeted gene therapy.

O'Riordan CR, Song A.

Methods Mol Biol. 2008;434:133-60. doi: 10.1007/978-1-60327-248-3_9.

PMID:
18470643
19.

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE.

Hum Gene Ther. 1999 May 20;10(8):1349-58.

PMID:
10365665
20.

Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.

Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY, Curiel DT, Haviv YS.

Neuro Oncol. 2007 Jul;9(3):280-90.

Items per page

Supplemental Content

Support Center